{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:43:25Z","timestamp":1792593805425,"version":"4.5.0"},"reference-count":32,"publisher":"MyJove Corporation","issue":"224","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/68725","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T23:01:35Z","timestamp":1760742095000},"source":"Crossref","is-referenced-by-count":0,"title":["Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity"],"prefix":"10.3791","author":[{"given":"Gargi","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vrinda","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goutam","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anindita","family":"Chakrabarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"issue":"10","key":"ref1","first-page":"2103","type":"journal-article","article-title":"Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer","volume":"9","author":"Xuhong","year":"2019","unstructured":"Xuhong, J. C., Qi, X. W., Zhang, Y., Jiang, J. Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer. Am J Cancer Res. 9 (10), 2103-2119 (2019).","journal-title":"Am J Cancer Res"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1533033820962140","DOI":"10.1177\/1533033820962140","type":"journal-article","article-title":"Tyrosine kinase inhibitors in the combination therapy of HER2-positive breast cancer","volume":"19","author":"Yang","year":"2020","unstructured":"Yang, X., Wu, D., Yuan, S. Tyrosine kinase inhibitors in the combination therapy of HER2-positive breast cancer. Technol Cancer Res Treat. 19, 1533033820962140 (2020).","journal-title":"Technol Cancer Res Treat"},{"issue":"4785","key":"ref3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","type":"journal-article","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","unstructured":"Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science. 235 (4785), 177-182 (1987).","journal-title":"Science"},{"issue":"6","key":"ref4","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.3390\/cancers15061766","type":"journal-article","article-title":"Hepatotoxicity of small molecule protein kinase inhibitors for cancer","volume":"15","author":"Vigan\u00f2","year":"2023","unstructured":"Vigan\u00f2, M. et al. Hepatotoxicity of small molecule protein kinase inhibitors for cancer. Cancers (Basel). 15 (6), 1766 (2023).","journal-title":"Cancers (Basel)"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clbc.2020.09.014","type":"journal-article","article-title":"Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the Phase III ExteNET trial","volume":"21","author":"Chan","year":"2021","unstructured":"Chan, A. et al. Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the Phase III ExteNET trial. Clin Breast Cancer. 21 (1), 80-91.e87 (2021).","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/hep.26175","type":"journal-article","article-title":"LiverTox: a website on drug-induced liver injury","volume":"57","author":"Hoofnagle","year":"2013","unstructured":"Hoofnagle, J. H., Serrano, J., Knoben, J. E., Navarro, V. J. LiverTox: a website on drug-induced liver injury. Hepatology. 57 (3), 873-874 (2013).","journal-title":"Hepatology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.39.1.1","type":"journal-article","article-title":"Cytochrome P-450 3A4: regulation and role in drug metabolism","volume":"39","author":"Guengerich","year":"1999","unstructured":"Guengerich, F. P. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol. 39, 1-17 (1999).","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"8","key":"ref8","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.3390\/ijms19082367","type":"journal-article","article-title":"Role of cytochrome P450 enzymes in the metabolic activation of tyrosine kinase inhibitors","volume":"19","author":"Jackson","year":"2018","unstructured":"Jackson, K. D., Durandis, R., Vergne, M. J. Role of cytochrome P450 enzymes in the metabolic activation of tyrosine kinase inhibitors. Int J Mol Sci. 19 (8), 2367 (2018).","journal-title":"Int J Mol Sci"},{"issue":"6","key":"ref9","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1002\/med.21577","type":"journal-article","article-title":"Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: implications for drug-drug interactions and hepatotoxicity","volume":"39","author":"Paludetto","year":"2019","unstructured":"Paludetto, M. N., Puisset, F., Chatelut, E., Arellano, C. Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: implications for drug-drug interactions and hepatotoxicity. Med Res Rev. 39 (6), 2105-2152 (2019).","journal-title":"Med Res Rev"},{"issue":"7","key":"ref10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1517\/17460441.2012.688744","type":"journal-article","article-title":"Drug discovery for a new generation of covalent drugs","volume":"7","author":"Kalgutkar","year":"2012","unstructured":"Kalgutkar, A. S., Dalvie, D. K. Drug discovery for a new generation of covalent drugs. Expert Opin Drug Discov. 7 (7), 561-581 (2012).","journal-title":"Expert Opin Drug Discov"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"576495","DOI":"10.3389\/fphar.2020.576495","type":"journal-article","article-title":"Protein binding of lapatinib and its N- and O-dealkylated metabolites interrogated by fluorescence, ultrafast spectroscopy and molecular dynamics simulations","volume":"11","author":"Andreu","year":"2020","unstructured":"Andreu, I. et al. Protein binding of lapatinib and its N- and O-dealkylated metabolites interrogated by fluorescence, ultrafast spectroscopy and molecular dynamics simulations. Front Pharmacol. 11, 576495 (2020).","journal-title":"Front Pharmacol"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12935-024-03418-x","type":"journal-article","article-title":"Promoting reactive oxygen species accumulation to overcome tyrosine kinase inhibitor resistance in cancer","volume":"24","author":"Lin","year":"2024","unstructured":"Lin, W. et al. Promoting reactive oxygen species accumulation to overcome tyrosine kinase inhibitor resistance in cancer. Cancer Cell Int. 24 (1), 239 (2024).","journal-title":"Cancer Cell Int"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"2002497","DOI":"10.1002\/advs.202002497","type":"journal-article","article-title":"Senescent tumor cells build a cytokine shield in colorectal cancer","volume":"8","author":"Choi","year":"2021","unstructured":"Choi, Y. W. et al. Senescent tumor cells build a cytokine shield in colorectal cancer. Adv Sci (Weinh). 8 (4), 2002497 (2021).","journal-title":"Adv Sci (Weinh)"},{"issue":"23-24","key":"ref14","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1101\/gad.343129.120","type":"journal-article","article-title":"Senescence and the SASP: many therapeutic avenues","volume":"34","author":"Birch","year":"2020","unstructured":"Birch, J., Gil, J. Senescence and the SASP: many therapeutic avenues. Genes Dev. 34 (23-24), 1565-1576 (2020).","journal-title":"Genes Dev"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12943-024-02096-7","type":"journal-article","article-title":"Cellular senescence and SASP in tumor progression and therapeutic opportunities","volume":"23","author":"Dong","year":"2024","unstructured":"Dong, Z. et al. Cellular senescence and SASP in tumor progression and therapeutic opportunities. Mol Cancer. 23 (1), 181 (2024).","journal-title":"Mol Cancer"},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cellsig.2011.12.006","type":"journal-article","article-title":"Emerging role of NF-\u03baB signaling in the induction of senescence-associated secretory phenotype (SASP)","volume":"24","author":"Salminen","year":"2012","unstructured":"Salminen, A., Kauppinen, A., Kaarniranta, K. Emerging role of NF-\u03baB signaling in the induction of senescence-associated secretory phenotype (SASP). Cell Signal. 24 (4), 835-845 (2012).","journal-title":"Cell Signal"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.coph.2013.05.013","type":"journal-article","article-title":"Changes in macrophage phenotype as the immune response evolves","volume":"13","author":"Lichtnekert","year":"2013","unstructured":"Lichtnekert, J., Kawakami, T., Parks, W. C., Duffield, J. S. Changes in macrophage phenotype as the immune response evolves. Curr Opin Pharmacol. 13 (4), 555-564 (2013).","journal-title":"Curr Opin Pharmacol"},{"issue":"11","key":"ref18","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/ni.2109","type":"journal-article","article-title":"Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils","volume":"12","author":"Galli","year":"2011","unstructured":"Galli, S. J., Borregaard, N., Wynn, T. A. Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat Immunol. 12 (11), 1035-1044 (2011).","journal-title":"Nat Immunol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3389\/fimmu.2014.00614","type":"journal-article","article-title":"Molecular mechanisms that influence the macrophage M1-M2 polarization balance","volume":"5","author":"Wang","year":"2014","unstructured":"Wang, N., Liang, H., Zen, K. Molecular mechanisms that influence the macrophage M1-M2 polarization balance. Front Immunol. 5, 614 (2014).","journal-title":"Front Immunol"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"102397","DOI":"10.1016\/j.autrev.2019.102397","type":"journal-article","article-title":"Macrophage M1\/M2 polarization and rheumatoid arthritis: a systematic review","volume":"18","author":"Tardito","year":"2019","unstructured":"Tardito, S. et al. Macrophage M1\/M2 polarization and rheumatoid arthritis: a systematic review. Autoimmun Rev. 18 (11), 102397 (2019).","journal-title":"Autoimmun Rev"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1189\/jlb.1012512","type":"journal-article","article-title":"Macrophage phenotypes during tissue repair","volume":"93","author":"Novak","year":"2013","unstructured":"Novak, M. L., Koh, T. J. Macrophage phenotypes during tissue repair. J Leukoc Biol. 93 (6), 875-881 (2013).","journal-title":"J Leukoc Biol"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.semcancer.2012.02.008","type":"journal-article","article-title":"New insights into chronic inflammation-induced immunosuppression","volume":"22","author":"Kanterman","year":"2012","unstructured":"Kanterman, J., Sade-Feldman, M., Baniyash, M. New insights into chronic inflammation-induced immunosuppression. Semin Cancer Biol. 22 (4), 307-318 (2012).","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s13046-019-1198-8","type":"journal-article","article-title":"Senescent thyrocytes and thyroid tumor cells induce M2-like macrophage polarization of human monocytes via a PGE2-dependent mechanism","volume":"38","author":"Mazzoni","year":"2019","unstructured":"Mazzoni, M. et al. Senescent thyrocytes and thyroid tumor cells induce M2-like macrophage polarization of human monocytes via a PGE2-dependent mechanism. J Exp Clin Cancer Res. 38 (1), 208 (2019).","journal-title":"J Exp Clin Cancer Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-4690-5-1","type":"journal-article","article-title":"Expression of infectious murine leukemia viruses by RAW264.7 cells, a potential complication for studies with a widely used mouse macrophage cell line","volume":"5","author":"Hartley","year":"2008","unstructured":"Hartley, J. W. et al. Expression of infectious murine leukemia viruses by RAW264.7 cells, a potential complication for studies with a widely used mouse macrophage cell line. Retrovirology. 5, 1 (2008).","journal-title":"Retrovirology"},{"issue":"5","key":"ref25","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1111\/jcmm.14277","type":"journal-article","article-title":"Overview of RAW264.7 for osteoclastogenesis study: phenotype and stimuli","volume":"23","author":"Kong","year":"2019","unstructured":"Kong, L., Smith, W., Hao, D. Overview of RAW264.7 for osteoclastogenesis study: phenotype and stimuli. J Cell Mol Med. 23 (5), 3077-3087 (2019).","journal-title":"J Cell Mol Med"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.intimp.2015.04.016","type":"journal-article","article-title":"D(-)-Salicin inhibits the LPS-induced inflammation in RAW264.7 cells and mouse models","volume":"26","author":"Li","year":"2015","unstructured":"Li, Y. et al. D(-)-Salicin inhibits the LPS-induced inflammation in RAW264.7 cells and mouse models. Int Immunopharmacol. 26 (2), 286-294 (2015).","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1517\/17425255.2.2.183","type":"journal-article","article-title":"Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies","volume":"2","author":"Castell","year":"2006","unstructured":"Castell, J. V., Jover, R., Mart\u00ednez-Jim\u00e9nez, C. P., G\u00f3mez-Lech\u00f3n, M. J. Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies. Expert Opin Drug Metab Toxicol. 2 (2), 183-212 (2006).","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13578-021-00683-5","type":"journal-article","article-title":"The hepatic senescence-associated secretory phenotype promotes hepatocarcinogenesis through Bcl3-dependent activation of macrophages","volume":"11","author":"Huang","year":"2021","unstructured":"Huang, Y. et al. The hepatic senescence-associated secretory phenotype promotes hepatocarcinogenesis through Bcl3-dependent activation of macrophages. Cell Biosci. 11 (1), 173 (2021).","journal-title":"Cell Biosci"},{"issue":"12","key":"ref29","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/s41580-024-00727-x","type":"journal-article","article-title":"The senescence-associated secretory phenotype and its physiological and pathological implications","volume":"25","author":"Wang","year":"2024","unstructured":"Wang, B., Han, J., Elisseeff, J. H., Demaria, M. The senescence-associated secretory phenotype and its physiological and pathological implications. Nat Rev Mol Cell Biol. 25 (12), 958-978 (2024).","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s41232-022-00197-8","type":"journal-article","article-title":"The roles and mechanisms of senescence-associated secretory phenotype (SASP): can it be controlled by senolysis","volume":"42","author":"Ohtani","year":"2022","unstructured":"Ohtani, N. The roles and mechanisms of senescence-associated secretory phenotype (SASP): can it be controlled by senolysis? Inflamm Regen. 42 (1), 11 (2022).","journal-title":"Inflamm Regen"},{"issue":"12","key":"ref31","first-page":"485","type":"journal-article","article-title":"The senescence-associated secretory phenotype (SASP) in the challenging future of cancer therapy and age-related diseases","volume":"9","author":"Cuollo","year":"2020","unstructured":"Cuollo, L., Antonangeli, F., Santoni, A., Soriani, A. The senescence-associated secretory phenotype (SASP) in the challenging future of cancer therapy and age-related diseases. Biology (Basel). 9 (12), 485 (2020).","journal-title":"Biology (Basel)"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-1-60761-344-2_6","type":"journal-article","article-title":"Heterologous expression of human membrane receptors in the yeast Saccharomyces cerevisiae","volume":"601","author":"Joubert","year":"2010","unstructured":"Joubert, O., Nehm\u00e9, R., Bidet, M., Mus-Veteau, I. Heterologous expression of human membrane receptors in the yeast Saccharomyces cerevisiae. Methods Mol Biol. 601, 87-103 (2010).","journal-title":"Methods Mol Biol"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/app.jove.com\/t\/68725\/drug-induced-senescence-liver-cells-promotes-m2-macrophage","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:21:15Z","timestamp":1792592475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jove.com\/t\/68725\/drug-induced-senescence-liver-cells-promotes-m2-macrophage"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":32,"journal-issue":{"issue":"224","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3791\/68725","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]}}}